NCT03544970 is a clinical trial in Fetal Anomaly, sponsored by Universitaire Ziekenhuizen KU Leuven.

Who is sponsoring NCT03544970?

NCT03544970 is sponsored by Universitaire Ziekenhuizen KU Leuven.

What condition does NCT03544970 study?

NCT03544970 studies Fetal Anomaly, Spinal Dysraphism, Chiari Malformation Type 2.

Is NCT03544970 still recruiting?

NCT03544970 is currently completed. Last updated 19 December 2018.

Last reviewed 2018-12-19 · How we verify

NCT03544970

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Audit of the Posterior Fossa Characterization in Open Spina Bifida Based on Tertiary Center Experience

Completed Last updated 19 December 2018

What this trial tests

trial in Fetal Anomaly in 316 participants. Completed in 31 October 2018.

Timeline

1 April 2017

Primary endpoint
26 October 2017

31 October 2018

Quick facts

Lead sponsor	Universitaire Ziekenhuizen KU Leuven
Status	Completed
Study type	OBSERVATIONAL
Enrollment	316
Start date	1 April 2017
Primary completion	26 October 2017
Estimated completion	31 October 2018
Sites	1 location across Belgium

Conditions studied

Fetal Anomaly — all drugs for Fetal Anomaly →
Spinal Dysraphism — all drugs for Spinal Dysraphism →
Chiari Malformation Type 2 — all drugs for Chiari Malformation Type 2 →

Sponsor

Universitaire Ziekenhuizen KU Leuven — full company profile →

Who can join

Eligibility, female only, with Fetal Anomaly or Spinal Dysraphism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Brain stem and posterior fossa measurements in spina bifida aperta fetuses to compare them with normal population. Additionally, Describe the difference between pre- and postoperative findings.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Fetal Anomaly

Currently open trials in the same condition.

NCT03398629 — Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies · recruiting

Other Universitaire Ziekenhuizen KU Leuven trials

Trials by the same sponsor.

NCT06831955 — LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer · Phase 2 · recruiting
NCT07356505 — Efficacy and Safety of Micra AV2 Transcatheter Pacing System · NA · recruiting
NCT07286968 — Gastro-Intestinal Digestion and Physiology After Bariatric Surgery · recruiting
NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
NCT07270536 — Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03544970 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitaire Ziekenhuizen KU Leuven
Last refreshed: 19 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03544970.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing